Cernostics and Deciphex Strategic Collaboration – To Evaluate the Use of AI-Driven Image Analysis Tools and Technology to Improve Upon Early Detection of Cancer in Patients with Barrett’s Esophagus

Collaboration to Allow the Develop AI-Based Histology Diagnostics and Prognostics for Barrett's Esophagus

September 15, 2020

Cernostics is a privately-held company focused on delivering next-generation cancer diagnostics and prognostics, and Deciphex, a leader in the application of AI to histology applications, announced today that they have entered into a strategic collaboration to jointly evaluate the use of AI-driven image analysis tools and technology to improve upon early detection of cancer in patients with Barrett’s esophagus.

Cernostics reports this collaboration combines the technological resources of both companies and will apply these to one of the world’s largest cohorts of Barrett’s esophagus patients with clinical outcome data, including patients who progressed to esophageal cancer.

Barrett’s esophagus, which affects more than three million Americans, occurs when chronic exposure to acid from the stomach causes the esophageal cell lining to deteriorate, creating an environment for cancer. Without treatment, Barrett’s can lead to esophageal adenocarcinoma, the fastest-rising cancer in the U.S. The current approach to managing Barrett’s is surveillance, involving regular endoscopic procedures with biopsies, monitoring for disease progression, and GERD-related drug therapy to control symptoms and prevent injury to the esophagus.

Cernostics previously developed and commercialized the TissueCypher® Barrett’s Esophagus Assay – the world’s first precision medicine test that predicts risk of developing esophageal cancer in patients with Barrett’s esophagus. Its patent-protected technology platform, TissueCypher®, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. TissueCypher provides actionable information to gastroenterologists, eliminating the uncertainty related to the management of Barrett’s esophagus patients.

This strategic collaboration between Deciphex and Cernostics – in part – will investigate whether histology slides may contain hidden prognostic indicators not discernible by the human eye, that can be unlocked with AI-based techniques. If successful, the companies have the option to integrate these novel indicators into a future generation of the TissueCypher Barrett’s Esophagus Assay or other commercial products.

Deciphex is a rapidly growing player in the Histology Artificial Intelligence space and has an interest in investigating the use of their AI solutions in the support of the development of histology-based prognostics for a wide array of disease applications. Deciphex plans to use this project as an example for how this approach can be leveraged broadly to enhance patient care.

Dr. Donal O’Shea, CEO of Deciphex, says, “We are excited to work with a leading player in the cancer prognostics space to progress our vision of unlocking hidden information from biopsies to enhance patient care and improve patient outcomes. We believe that AI has the power to see beyond the human eye and release previously unappreciated, high value, data from the histology specimen.”

Mike Hoerres, CEO of Cernostics, says, “We are witnessing unprecedented advances in AI-driven image analysis tools for pathology. We believe collaborating with Donal and his team at Deciphex is one of the best ways to accelerate and enhance product development for the benefit of patients, clinicians, and the payer communities.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy